Gene expression profile in the salivary glands of primary Sjögren's syndrome patients before and after treatment with rituximab

Arthritis and Rheumatism

Volumn 62, Issue 8, 2010, Pages 2262-2271

  Devauchelle Pensec, Valérie ^a   Cagnard, Nicolas ^b   Pers, Jacques Olivier ^c   Youinou, Pierre ^c   Saraux, Alain ^a   Chiocchia, Gilles ^b,d  

^a SERVICE DE RHUMATOLOGIE   (France)

^b INSTITUT COCHIN   (France)

^c CHU MORVAN   (France)

^d HÔPITAL AMBROISE PARÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; B LYMPHOCYTE RECEPTOR; BETA N ACETYLHEXOSAMINIDASE B; BINDING PROTEIN; CELL NUCLEUS RECEPTOR; CHECKPOINT KINASE 2; CYB5R1 PROTEIN; CYTOCHROME B5 REDUCTASE; ELAFIN; GAMMA INTERFERON; GBP2 PROTEIN; GLOBIN; H2AFJ PROTEIN; HISTONE H2A; NONSTEROID ANTIINFLAMMATORY AGENT; NR2F6 PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE GAMMA; PROTEIN; PROTEIN CDC42; RITUXIMAB; RNA; RUSC1 PROTEIN; SCGB1D1 PROTEIN; SCGB2A1 PROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; B LYMPHOCYTE; CELL INFILTRATION; CLINICAL ARTICLE; CLINICAL TRIAL; DOWN REGULATION; DRUG EFFICACY; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMAN; HUMAN TISSUE; MALE; MICROARRAY ANALYSIS; NUCLEIC ACID AMPLIFICATION; OPEN STUDY; PATIENT CODING; PRIMARY SJOGREN SYNDROME; PRIORITY JOURNAL; RNA EXTRACTION; SALIVARY GLAND BIOPSY; SELF EVALUATION; SIGNAL TRANSDUCTION; SJOEGREN SYNDROME; TREATMENT RESPONSE; UPREGULATION;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; B-LYMPHOCYTES; CLUSTER ANALYSIS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MALE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SALIVARY GLANDS; SIGNAL TRANSDUCTION; SJOGREN'S SYNDROME; TREATMENT OUTCOME;

EID: 77955404822     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.27509     Document Type: Article

References (41)

1. Gannot G, Lancaster HE, Fox PC. Clinical course of primary Sjögren's syndrome: salivary, oral, and serologic aspects. J Rheumatol 2000;27:1905-9. (Pubitemid 30670484)
2. Soliotis FC, Moutsopoulos HM. Sjögren's syndrome. Autoimmunity 2004;37:305-7.
3. Talal N, Sylvester RA, Daniels TE, Greenspan JS, Williams RC Jr. T and B lymphocytes in peripheral blood and tissue lesions in Sjögren's syndrome. J Clin Invest 1974;53:180-9.
4. Christodoulou MI, Kapsogeorgou EK, Moutsopoulos NM, Moutsopoulos HM. Foxp3+ T-regulatory cells in Sjögren's syndrome: correlation with the grade of the autoimmune lesion and certain adverse prognostic factors. Am J Pathol 2008;173:1389-96.
5. Mitsias DI, Tzioufas AG, Veiopoulou C, Zintzaras E, Tassios IK, Kogopoulou O, et al. The Th1/Th2 cytokine balance changes with the progress of the immunopathological lesion of Sjögren's syndrome. Clin Exp Immunol 2002;128:562-8.
6. Gottenberg JE, Cagnard N, Lucchesi C, Letourneur F, Mistou S, Lazure T, et al. Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjögren's syndrome. Proc Natl Acad Sci U S A 2006;103:2770-5. (Pubitemid 43306624)
7. Binard A, Le Pottier L, Devauchelle-Pensec V, Saraux A, Youinou P, Pers JO. Is the blood B-cell subset profile diagnostic for Sjögren syndrome? Ann Rheum Dis 2009;68:1447-52.
8. Daridon C, Pers JO, Devauchelle V, Martins-Carvalho C, Hutin P, Pennec YL, et al. Identification of transitional type II B cells in the salivary glands of patients with Sjögren's syndrome. Arthritis Rheum 2006;54:2280-8.
9. Jonsson MV, Szodoray P, Jellestad S, Jonsson R, Skarstein K. Association between circulating levels of the novel TNF family members APRIL and BAFF and lymphoid organization in primary Sjögren's syndrome. J Clin Immunol 2005;25:189-201. (Pubitemid 40884044)
10. Daridon C, Devauchelle V, Hutin P, Le Berre R, Martins-Carvalho C, Bendaoud B, et al. Aberrant expression of BAFF by B lymphocytes infiltrating the salivary glands of patients with primary Sjögren's syndrome. Arthritis Rheum 2007;56:1134-44. (Pubitemid 46608638)
11. Devauchelle-Pensec V, Pennec Y, Morvan J, Pers JO, Daridon C, Jousse-Joulin S, et al. Improvement of Sjögren's syndrome after two infusions of rituximab (anti-CD20). Arthritis Rheum 2007;57:310-7. (Pubitemid 47164095)
12. Polyak MJ, Li H, Shariat N, Deans JP. CD20 homo-oligomers physically associate with the B cell antigen receptor: dissociation upon receptor engagement and recruitment of phosphoproteins and calmodulin-binding proteins. J Biol Chem 2008;283:18545-52.
13. Cambridge G, Isenberg DA, Edwards JC, Leandro MJ, Migone TS, Teodorescu M, et al. B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response. Ann Rheum Dis 2008;67:1011-6. (Pubitemid 351956665)
14. Jais JP, Haioun C, Molina TJ, Rickman DS, de Reynies A, Berger F, et al. The expression of 16 genes related to the cell of origin and immune response predicts survival in elderly patients with diffuse large B-cell lymphoma treated with CHOP and rituximab. Leukemia 2008;22:1917-24.
15. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al, and the European Study Group on Classification Criteria for Sjögren's Syndrome. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61:554-8.
16. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350:2572-81. (Pubitemid 38758544)
17. Pijpe J, van Imhoff GW, Spijkervet FK, Roodenburg JL, Wolbink GJ, Mansour K, et al. Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study. Arthritis Rheum 2005;52:2740-50. (Pubitemid 41369102)
18. Teppo H, Revonta M. A follow-up study of minimally invasive lip biopsy in the diagnosis of Sjögren's syndrome. Clin Rheumatol 2007;26:1099-103. (Pubitemid 46863952)
19. Chisholm DM, Mason DK. Labial salivary gland biopsy in Sjögren's disease. J Clin Pathol 1968;21:656-60.
20. Pers JO, Devauchelle V, Daridon C, Bendaoud B, Le Berre R, Bordron A, et al. BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjögren's syndrome. Arthritis Rheum 2007;56:1464-77.
21. Trottier MD, Newsted MM, King LE, Fraker PJ. Natural glucocorticoids induce expansion of all developmental stages of murine bone marrow granulocytes without inhibiting function. Proc Natl Acad Sci U S A 2008;105:2028-33.
22. Petroni KC, Shen L, Guyre PM. Modulation of human polymorphonuclear leukocyte IgG Fc receptors and Fc receptor-mediated functions by IFN-γ and glucocorticoids. J Immunol 1988;140:3467-72.
23. Cox G. Glucocorticoid treatment inhibits apoptosis in human neutrophils: separation of survival and activation outcomes. J Immunol 1995;154:4719-25.
24. Laakko T, Fraker P. Rapid changes in the lymphopoietic and granulopoietic compartments of the marrow caused by stress levels of corticosterone. Immunology 2002;105:111-9. (Pubitemid 34128046)
25. Carlotti E, Palumbo GA, Oldani E, Tibullo D, Salmoiraghi S, Rossi A, et al. FcγRIIIA and FcγRIIA polymorphisms do not predict clinical outcome of follicular non-Hodgkin's lymphoma patients treated with sequential CHOP and rituximab. Haematologica 2007;92:1127-30. (Pubitemid 350144222)
26. Reid PT, Marsden ME, Cunningham GA, Haslett C, Sallenave JM. Human neutrophil elastase regulates the expression and secretion of elafin (elastase-specific inhibitor) in type II alveolar epithelial cells. FEBS Lett 1999;457:33-7. (Pubitemid 29387404)
27. Williams SE, Brown TI, Roghanian A, Sallenave JM. SLPI and elafin: one glove, many fingers. Clin Sci (Lond) 2006;110:21-35.
28. Lehrer RI, Xu G, Abduragimov A, Dinh NN, Qu XD, Martin D, et al. Lipophilin, a novel heterodimeric protein of human tears. FEBS Lett 1998;432:163-7.
29. Mukherjee AB, Zhang Z, Chilton BS. Uteroglobin: a steroidinducible immunomodulatory protein that founded the Secretoglobin superfamily [published erratum appears in Endocr Rev 2008;29:131]. Endocr Rev 2007;28:707-25.
30. Levin SW, Butler JD, Schumacher UK, Wightman PD, Mukherjee AB. Uteroglobin inhibits phospholipase A2 activity. Life Sci 1986;38:1813-9.
31. Lesur O, Bernard A, Arsalane K, Lauwerys R, Begin R, Cantin A, et al. Clara cell protein (CC-16) induces a phospholipase A2- mediated inhibition of fibroblast migration in vitro. Am J Respir Crit Care Med 1995;152:290-7.
32. Kino-Ohsaki J, Nishimori I, Morita M, Okazaki K, Yamamoto Y, Onishi S, et al. Serum antibodies to carbonic anhydrase I and II in patients with idiopathic chronic pancreatitis and Sjögren's syndrome. Gastroenterology 1996;110:1579-86.
33. Nguyen C, Singson E, Kim JY, Cornelius JG, Attia R, Doyle ME, et al. Sjögren's syndrome-like disease of C57BL/6.NOD-Aec1 Aec2 mice: gender differences in keratoconjunctivitis sicca defined by a cross-over in the chromosome 3 Aec1 locus. Scand J Immunol 2006;64:295-307. (Pubitemid 44215120)
34. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994;83:435-45.
35. Walshe CA, Beers SA, French RR, Chan CH, Johnson PW, Packham GK, et al. Induction of cytosolic calcium flux by CD20 is dependent upon B cell antigen receptor signaling. J Biol Chem 2008;283:16971-84.
36. Teng YK, Levarht EW, Hashemi M, Bajema IM, Toes RE, Huizinga TW, et al. Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment. Arthritis Rheum 2007;56:3909-18.
37. Thurlings RM, Vos K, Wijbrandts CA, Zwinderman AH, Gerlag DM, Tak PP. Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response. Ann Rheum Dis 2008;67:917-25.
38. Mavragani CP, Niewold TB, Moutsopoulos NM, Pillemer SR, Wahl SM, Crow MK. Augmented interferon-α pathway activation in patients with Sjögren's syndrome treated with etanercept. Arthritis Rheum 2007;56:3995-4004.
39. Wildenberg ME, van Helden-Meeuwsen CG, van de Merwe JP, Drexhage HA, Versnel MA. Systemic increase in type I interferon activity in Sjögren's syndrome: a putative role for plasmacytoid dendritic cells. Eur J Immunol 2008;38:2024-33.
40. Gottenberg JE, Chiocchia G. Dendritic cells and interferonmediated autoimmunity. Biochimie 2007;89:856-71.
41. Bekeredjian-Ding IB, Wagner M, Hornung V, Giese T, Schnurr M, Endres S, et al. Plasmacytoid dendritic cells control TLR7 sensitivity of naive B cells via type I IFN. J Immunol 2005;174:4043-50.